Lineage Cell Therapeutics (LCTX) Projected to Announce Earnings on Thursday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Lineage Cell Therapeutics to post earnings of ($0.03) per share and revenue of $1.8420 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The firm had revenue of $1.73 million for the quarter, compared to the consensus estimate of $3.60 million. Lineage Cell Therapeutics had a negative return on equity of 89.36% and a negative net margin of 434.44%. On average, analysts expect Lineage Cell Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Lineage Cell Therapeutics Stock Performance

LCTX traded up $0.03 during trading on Tuesday, hitting $1.14. The stock had a trading volume of 248,389 shares, compared to its average volume of 1,289,245. The stock has a 50 day simple moving average of $1.22 and a two-hundred day simple moving average of $1.46. Lineage Cell Therapeutics has a twelve month low of $0.95 and a twelve month high of $2.09. The company has a market capitalization of $282.96 million, a PE ratio of -3.91 and a beta of 1.53.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Canaccord Genuity Group began coverage on Lineage Cell Therapeutics in a research report on Tuesday, April 28th. They issued a “buy” rating and a $9.00 price objective for the company. D. Boral Capital reiterated a “buy” rating and issued a $3.00 price target on shares of Lineage Cell Therapeutics in a research note on Monday, May 4th. Finally, HC Wainwright restated a “buy” rating on shares of Lineage Cell Therapeutics in a research note on Tuesday, July 14th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $6.25.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its position in shares of Lineage Cell Therapeutics by 1,578.9% in the first quarter. Royal Bank of Canada now owns 528,656 shares of the company’s stock valued at $237,000 after buying an additional 497,168 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Lineage Cell Therapeutics by 9.9% during the first quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock worth $91,000 after purchasing an additional 18,092 shares in the last quarter. XTX Topco Ltd raised its position in shares of Lineage Cell Therapeutics by 117.8% during the 2nd quarter. XTX Topco Ltd now owns 94,054 shares of the company’s stock worth $85,000 after purchasing an additional 50,876 shares during the last quarter. Jump Financial LLC acquired a new stake in Lineage Cell Therapeutics in the 2nd quarter worth about $28,000. Finally, WINTON GROUP Ltd acquired a new stake in Lineage Cell Therapeutics in the 2nd quarter worth about $69,000. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.